<DOC>
	<DOCNO>NCT03003962</DOCNO>
	<brief_summary>This randomize , open-label , multi-center Phase III study determine efficacy safety durvalumab versus platinum-based SoC chemotherapy first-line treatment advance NSCLC patient epidermal growth factor receptor ( EGFR ) anaplastic lymphoma kinase ( ALK ) wild-type PD-L1-high expression</brief_summary>
	<brief_title>A Study Durvalumab Versus Standard Care Advanced Non Small-Cell Lung Cancer</brief_title>
	<detailed_description>Patients randomize 1:1 ratio 2 treatment arm ( durvalumab SOC therapy ) . The Co-primary objective study assess efficacy durvalumab compare SoC term PFS ( Progression Free Survival ) OS ( Overall Survival ) patient NSCLC</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Aged least 18 year Documented evidence Stage IV NSCLC No sensitize EGFR mutation ALK rearrangement PDL1 expression least 25 % Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Prior chemotherapy systemic therapy advance NSCLC Prior exposure immunemediated therapy , include , limited , anticytotoxic T lymphocyteassociated antigen 4 ( CTLA4 ) , antiprogrammed cell death1 ( PD1 ) , antiprogrammed cell death ligand 1 ( PDL1 ) , anti PDL2 antibody , exclude therapeutic anticancer vaccine Brain metastasis spinal cord compression unless patient stable steroid least 14 day prior start study treatment Mixed smallcell lung cancer NSCLC histology , sarcomatoid variant Active prior document autoimmune inflammatory disorder ( e.g. , colitis Crohn 's disease ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>PD-L1</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>PFS</keyword>
	<keyword>OS</keyword>
</DOC>